DelveInsight’s “Intrahepatic Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Intrahepatic Cholangiocarcinoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Intrahepatic Cholangiocarcinoma Market is an evolving segment of the global healthcare landscape, driven by the increasing Intrahepatic Cholangiocarcinoma prevalence of the disorder and the continuous development of innovative treatment options. The Intrahepatic Cholangiocarcinoma Market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.
Discover Key Insights into the Intrahepatic Cholangiocarcinoma Market with DelveInsight’s In-Depth Report @ Intrahepatic Cholangiocarcinoma Market Size
Key Takeaways from the Intrahepatic Cholangiocarcinoma Market Report
- In November 2024:- Jazz Pharmaceuticals- The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician’s choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.
- In 2023, the US accounted for ~30% of the total incident cases of cholangiocarcinoma in the 7MM.
- As per the analysis, there were ~6,400 cases of intrahepatic cholangiocarcinoma in Japan, in 2023.
- In 2023, the mutation-specific cases of intrahepatic cholangiocarcinoma were highest in TP53 mutations, followed by KRAS mutations in the US.
- The leading intrahepatic cholangiocarcinoma companies such as Virogin Biotech Ltd., Syndax Pharmaceuticals, Delcath Systems Inc., TriSalus Life Sciences, Inc., AstraZeneca, Relay Therapeutics, Inc., Kinnate Biopharma, Elucida Oncology, Lisata Therapeutics, Inc., Amgen, Jazz Pharmaceuticals, BeiGene, Ltd., and others.
- The Intrahepatic cholangiocarcinoma therapies such as VG161, SNDX-6352, Cisplatin and Gemcitabine, SD-101, Y-90 With Durvalumab/Gem/Cis, RLY-4008, KIN-3248, ELU001, LSTA1, Bemarituzumab, ZW25 (Zanidatamab), and others.
Stay ahead in the Intrahepatic Cholangiocarcinoma Therapeutics Market with DelveInsight’s Strategic Report @ Intrahepatic Cholangiocarcinoma Market Outlook
Intrahepatic Cholangiocarcinoma Epidemiology Segmentation in the 7MM
- Total Intrahepatic Cholangiocarcinoma Incident Cases
- Total Intrahepatic Cholangiocarcinoma Incident Cases
- Intrahepatic Cholangiocarcinoma Mutation-specific Cases
- Intrahepatic Cholangiocarcinoma Age-specific Cases
- Intrahepatic Cholangiocarcinoma Stage-specific Cases
- Total Intrahepatic Cholangiocarcinoma Treated Cases
Download the report to understand which factors are driving Intrahepatic Cholangiocarcinoma epidemiology trends @ Intrahepatic Cholangiocarcinoma Prevalence
Intrahepatic Cholangiocarcinoma Marketed Drugs
- PEMAZYRE (pemigatinib): Incyte Corporation
PEMAZYRE (pemigatinib) is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
- ROZLYTREK (entrectinib): Roche
ROZLYTREK (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test, adult and pediatric patients older than 1 month of age with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy..
- TIBSOVO (ivosidenib): Servier/Agios Pharmaceuticals
TIBSOVO (ivosidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test, for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated. The recommended dosage of TIBSOVO is 500 mg taken orally once daily until disease progression or unacceptable toxicity.
Intrahepatic Cholangiocarcinoma Emerging Drugs
- CTX-009: Compass Therapeutics
CTX-009 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. Preclinical and early clinical data of CTX-009 suggest that blockade of both pathways provides robust antitumor activity across several solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic, and non-small cell lung cancer. Partial responses to CTX-009 as monotherapy have been observed in heavily pre-treated patients with cancer who were resistant to currently approved anti-VEGF therapies.
- Tinengotinib: TransThera Sciences
Tinengotinib is an innovative, global Phase III stage spectrum-selective kinase inhibitor that exerts antitumor effects by targeting tumor cells and improving the tumor microenvironment. Ongoing clinical trials in the US and China have revealed the potential of Tinengotinib to be efficacious in various solid tumors. It was granted the ODD and FTD by the FDA for the treatment of cholangiocarcinoma.
- Silmitasertib (CX-4945): Senhwa Biosciences
Silmitasertib (CX-4945), a synthetically derived small molecule, is provided as a sodium salt in hard gelatin capsule shells with oral administration. CK2 (Casein kinase 2) is a protein kinase that has elevated activity in many cancers and has a direct role in DNA damage repair. The DNA repair pathways enable tumor cells to survive damage induced by treatment with chemotherapeutic agents. Inhibitors of DNA repair pathways have been shown to increase the efficacy of DNA-damaging chemotherapeutic drugs when these are used in combination.
Get In-Depth Knowledge on Intrahepatic Cholangiocarcinoma Market Trends and Forecasts with DelveInsight @ Intrahepatic Cholangiocarcinoma Treatment Market
Intrahepatic Cholangiocarcinoma Market Outlook
The Intrahepatic Cholangiocarcinoma market is evolving with promising advancements in targeted and personalized treatments. Although intrahepatic cholangiocarcinoma remains challenging due to late diagnosis and its rarity, the development of drugs targeting FGFR2 and IDH-1 mutations offers new hope. Increased research, improved molecular diagnostics, and the rise of precision medicine are driving market growth. However, high treatment costs and recruitment difficulties in clinical trials are ongoing challenges. The future outlook is positive, with expectations for expanded treatment options and improved patient outcomes as new therapies gain approval and become available.
Scope of the Intrahepatic Cholangiocarcinoma Market
- Coverage- 7MM
- Intrahepatic cholangiocarcinoma companies- Virogin Biotech Ltd., Syndax Pharmaceuticals, Delcath Systems Inc., TriSalus Life Sciences, Inc., AstraZeneca, Relay Therapeutics, Inc., Kinnate Biopharma, Elucida Oncology, Lisata Therapeutics, Inc., Amgen, Jazz Pharmaceuticals, BeiGene, Ltd., and others are developing novel intrahepatic cholangiocarcinoma drugs that can be available in the intrahepatic cholangiocarcinoma market in the coming years.
- Intrahepatic cholangiocarcinoma Therapies- VG161, SNDX-6352, Cisplatin and Gemcitabine, SD-101, Y-90 With Durvalumab/Gem/Cis, RLY-4008, KIN-3248, ELU001, LSTA1, Bemarituzumab, ZW25 (Zanidatamab), and others.
- Intrahepatic Cholangiocarcinoma Market Dynamics: Intrahepatic Cholangiocarcinoma Market Drivers and Barriers
- Intrahepatic Cholangiocarcinoma Market Access and Reimbursement, Unmet Needs and Future Perspectives
Unlock Strategic Insights with DelveInsight’s Comprehensive Intrahepatic Cholangiocarcinoma Market Report @ Intrahepatic Cholangiocarcinoma Market Drivers and Barriers
Table of Content
1. Key Insights
2. Executive Summary of Intrahepatic Cholangiocarcinoma
3. Competitive Intelligence Analysis for Intrahepatic Cholangiocarcinoma
4. Intrahepatic Cholangiocarcinoma: Market Overview at a Glance
5. Intrahepatic Cholangiocarcinoma: Disease Background and Overview
6. Patient Journey
7. Intrahepatic Cholangiocarcinoma Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Intrahepatic Cholangiocarcinoma Unmet Needs
10. Key Endpoints of Intrahepatic Cholangiocarcinoma Treatment
11. Intrahepatic Cholangiocarcinoma Marketed Products
12. Intrahepatic Cholangiocarcinoma Emerging Therapies
13. Intrahepatic Cholangiocarcinoma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Intrahepatic Cholangiocarcinoma
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/